Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02947347
Title Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

follicular lymphoma

Therapies

Ibrutinib

Ibrutinib + Rituximab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.